Breast Cancer Prognosis: Weighing the Evidence on Weight and Physical Activity

Publication
Article
OncologyONCOLOGY Vol 24 No 4
Volume 24
Issue 4

Traditionally host factors such as weight and physical activity have not been considered in the overall treatment of breast cancer patients. In this issue of ONCOLOGY, Nagaiah and Abraham review the epidemiologic and biologic evidence evaluating the relationships among obesity, physical activity, and both breast cancer recurrence and mortality, and in doing so, advocate weight management and exercise for breast cancer patients.

Traditionally host factors such as weight and physical activity have not been considered in the overall treatment of breast cancer patients. In this issue of ONCOLOGY, Nagaiah and Abraham review the epidemiologic and biologic evidence evaluating the relationships among obesity, physical activity, and both breast cancer recurrence and mortality, and in doing so, advocate weight management and exercise for breast cancer patients.

Body Mass Index

Body mass index (BMI), calculated as weight (kg) divided by squared height (m2), is currently the most commonly used measurement of obesity in both epidemiologic and clinical studies. Based on World Health Organization categorizations, a BMI ≥ 25 kg/m2 is considered overweight and ≥ 30 kg/m2 is obese. However, these cutoffs are likely to vary for some racial/ethnic groups.

Being overweight or obese is an established risk factor for postmenopausal breast cancer, particularly the hormone receptor–positive phenotype.[1] Increased estrogen production resulting from the peripheral conversion of estrogen by aromatase in adipose tissue is believed to be an important etiologic factor in this relationship.[2] Growing evidence links obesity to breast cancer recurrence and mortality. Nagaiah and Abraham highlight seven studies examining obesity and breast cancer recurrence and/or mortality,[3-9] and we have identified five additional studies.[10-14] The majority of these studies observed a positive association between obesity and overall mortality, with estimates ranging from a 10% to 65% increase in mortality for obese women. Several studies also found modest positive associations between obesity and breast cancer–specific mortality, disease-free survival, and recurrence.

As suggested by the authors, the underlying biologic mechanisms are still to be elucidated. In addition to an increase in the peripheral conversion of androgens to estrogens in adipose tissue, perturbations in glucose, insulin, and insulin-like growth factor (IGF-1) levels, along with alterations in sex hormone–binding globulin, as well as adipokines such as leptin and adiponectin, and inflammation are believed to play a role. These factors may also be influenced by physical activity, which makes it hard to separate the effects of weight from physical activity.

Some evidence suggests that obese women are more likely to be diagnosed with larger, higher-grade, and hormone receptor–negative tumors.[3] This could be biologic and/or due to differences in screening practices and limitations of screening devices in this group.[15,16] However this is unlikely to completely explain the positive association between obesity and mortality, since most studies have adjusted for stage at diagnosis and tumor size. Differences in study design, including timing of obesity measurements, as well as differences in tumor phenotype, comorbidities, treatment, and other prognostic factors may explain some of the reported inconsistencies among studies.

Timing of BMI Measurement

Most studies have focused on BMI at or near diagnosis, though some have considered BMI at 1 year or more prior to diagnosis. The availability of repeated measures of BMI prior to and postdiagnosis would be ideal, but such information can be difficult to obtain. BMI measured at diagnosis may represent tumor or treatment-related effects, which tend to be transient and therefore less likely to significantly affect breast cancer mortality, whereas obesity measured 1 to 5 years prior to diagnosis or postdiagnosis may be more representative of a woman’s average body weight. A few studies have looked at the effect of weight change on breast cancer mortality with mixed results [9-11].

Other Factors That May Impact Breast Cancer Outcomes in Obese Women

In addition, factors such as age, smoking, hormone receptor status, menopausal status, and use of hormone therapy (HT) may modify the association between BMI and breast cancer outcomes and should be taken into consideration in analyses. The Nurses Health Study observed that BMI prior to diagnosis was strongly associated with breast cancer mortality in “never-smokers” and premenopausal women, but not in smokers or postmenopausal women.[10] In addition, a study of postmenopausal breast cancer patients found that obese women who had ever used HT prior to diagnosis had a two-fold increased risk of breast cancer mortality, while obese “never-users” were not at increased risk.[14] So far, studies have not been consistent in collecting or examining these factors.

Comorbid conditions prevalent in obese women, such as diabetes, may also affect both overall survival and breast cancer mortality.[17] Furthermore, obese women may not receive the same treatment as non-obese women due to concerns about side effects, which may have an impact on survival.[3]

Physical Activity

Like obesity, decreased physical activity has been consistently associated with breast cancer incidence, but fewer studies have considered its effect on breast cancer recurrence and prognosis.[18] The authors cite three studies of physical activity, recurrence, and mortality,[19-21] and we noted five additional studies that have recently been published.[22-26] Many studies found inverse associations between physical activity and all-cause mortality, but there is less evidence for breast cancer mortality and very little evidence on recurrence.

Similar to considerations that arise when studying obesity, the concepts of when to measure physical activity and how physical activity interacts with host factors are important issues. Though all the studies reviewed used metabolic equivalent task hours (METs) to quantify physical activity, some studies measured lifetime physical activity, whereas others focused on physical activity prior to diagnosis or following diagnosis and treatment. In addition, some studies considered total activity, while others measured recreational, occupational, and household activity. Studies that report lifetime physical activity rely on participants’ self-report of past activity, which may lead to biased effect estimates.

It is unclear to what extent observed beneficial effects of physical activity depend on body weight or weight loss. Some studies found similar effects of physical activity regardless of BMI,[20,21,23] while others found that physical activity reduced mortality only in overweight and obese women.[19,24,25] In addition, associations among physical activity, recurrence, and mortality may not be causal, but rather reflect underlying disease severity, particularly when physical activity is measured near diagnosis and/or treatment. This could result in an observed protective effect between physical activity and recurrence/mortality-a case of reverse causation. A greater understanding of the underlying biology will help tease out these associations.

Conclusions

In summary, there is enough evidence to support the integration of weight management and physical activity into the clinical care of breast cancer patients, particularly those who are overweight or obese. Well designed epidemiologic studies and intervention trials should focus on evaluating measures of adiposity prior to diagnosis, postdiagnosis, and following treatment in parallel with mechanistic studies to further increase our understanding of the underlying biology. Understanding how host factors interact with obesity would aid in the counseling of patients as well as in targeting obesity interventions to specific groups of breast cancer patients.

Financial Disclosure:The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.

References:

References

1. Cleary MP, Grossman ME: Minireview: Obesity and breast cancer: The estrogen connection. Endocrinology 150:2537-2542, 2009.

2. Ahn J, Schatzkin A, Lacey JV Jr, et al: Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 167:2091-2102, 2007.

3. Litton JK, Gonzalez-Angulo AM, Warneke CL, et al: Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26:4072-4077, 2008.

4. Berclaz G, Li S, Price KN, et al: Body mass index as a prognostic feature in operable breast cancer: The International Breast Cancer Study Group experience. Annals of Oncology 15:875-884, 2004.

5. Dawood S, Broglio K, Gonzalez-Angulo AM, et al: Prognostic value of body mass index in locally advanced breast cancer. Clin Cancer Res 14:1718-1725, 2008.

6. Enger SM, Greif JM, Polikoff J, et al: Body weight correlates with mortality in early-stage breast cancer. Arch Surg 139:954-960, 2004.

7. Tao MH, Shu X, Ruan Z, et al: Association of overweight with breast cancer survival. Am J Epidemiol 163:101-107, 2006.

8. Dignam JJ, Wieand K, Johnson KA, et al: Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat 97:245-254, 2006.

9. Caan BJ, Kwan ML, Hartzell G, et al: Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control 19:1319-1328, 2008.

10. Kroenke CH, Chen WY, Rosner B, et al: Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23:1370-1378, 2005.

11. Cleveland RJ, Eng SM, Abrahamson PE, et al: Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers Prev 16:1803-1811, 2007.

12. Majed B, Moreau T, Senouci K, et al: Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 111:329-342, 2008.

13. Dal Maso L, Zucchetto A, Talamini R, et al, for the Prospective Analysis of Case-control studies on Environmental factors and health (PACE) study group. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer 123:2188-2194, 2008.

14. Rosenberg L, Czene K, Hall P: Obesity and poor breast cancer prognosis: An illusion because of hormone replacement therapy? Br J Cancer 100:1486-1491, 2009.

15. Maruthur NM, Bolen S, Brancati FL, et al: Obesity and mammography: A systematic review and meta-analysis. J Gen Intern Med 24:665-677, 2009.

16. Elmore JG, Carney PA, Abraham LA, et al: The association between obesity and screening mammography accuracy. Arch Intern Med 164:1140-1147, 2004.

17. Barone BB, Yeh HC, Snyder CF, et al: Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA 300:2754-2764, 2008.

18. Neilson HK, Friedenreich CM, Brockton NT, et al: Physical activity and postmenopausal breast cancer: Proposed biologic mechanisms and areas for future research. Cancer Epidemiol Biomarkers Prev 18:11-27, 2009.

19. Abrahamson PE, Gammon MD, Lund MJ, et al: Recreational physical activity and survival among young women with breast cancer. Cancer 107:1777-1785, 2006.

20. Holick CN, Newcomb PA, Trentham-Dietz A, et al: Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 17:379-386, 2008.

21. Holmes MD, Chen WY, Feskanich D, et al: Physical activity and survival after breast cancer diagnosis. JAMA 293:2479-2486, 2005.

22. Pierce JP, Stefanick ML, Flatt SW, et al: Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 25:2345-2351, 2007.

23. Irwin ML, Smith AW, McTiernan A, et al: Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: The health, eating, activity, and lifestyle study. J Clin Oncol 26:3958-3964, 2008.

24. Sternfeld B, Weltzien E, Quesenberry CP, et al: Physical activity and risk of recurrence and mortality in breast cancer survivors: Findings from the LACE study. Cancer Epidemiol Biomarkers Prev 18:87-95, 2009.

25. West-Wright CN, Henderson KD, Sullivan-Halley J, et al: Long-term and recent recreational physical activity and survival after breast cancer: The California Teachers Study. Cancer Epidemiol Biomarkers Prev 18:2851-2859, 2009.

26. Friedenreich CM, Gregory J, Kopciuk KA, et al: Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer 124:1954-1962, 2009.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.